- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03560752
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients After Stem Cell Transplant
Study Overview
Status
Conditions
- Hematopoietic and Lymphoid Cell Neoplasm
- Hodgkin Lymphoma
- Myelofibrosis
- Chronic Lymphocytic Leukemia
- Non-Hodgkin Lymphoma
- Myelodysplastic Syndrome
- Myelodysplastic/Myeloproliferative Neoplasm
- Acute Myeloid Leukemia in Remission
- Acute Lymphoblastic Leukemia in Remission
- Cytomegalovirus Positive
- Donor
- Hematopoietic Cell Transplant Recipient
- Accelerated Phase CML, BCR-ABL1 Positive
- Chronic Phase CML, BCR-ABL1 Positive
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Establish the feasibility and safety of priming CMV immunity in donors by Triplex vaccination prior to peripheral blood stem cell (PBSC) harvest.
SECONDARY OBJECTIVES:
I. Examine if Triplex vaccination of hematopoietic stem cell transplant (HCT) donors has an impact on CMV events.
OUTLINE:
Donors receive multi-peptide CMV-modified vaccinia Ankara vaccine injection between days -60 and -10 prior to granulocyte colony stimulating factor mobilization. Participants undergo hematopoietic cell transplantation on day 0.
After completion of study treatment, participants are followed up for 1 year.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- DONOR: Ability to comprehend the investigational nature of the study and provide informed consent
- DONOR: Willing to receive Triplex vaccination, a minimum of 14 days prior to the PBSC collection
- DONOR VACCINATION: Donors are eligible to be vaccinated prior to the determination of their human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and human T-cell lymphotropic virus (HTLV) status. The exclusion criteria for transplant is independent of eligibility for vaccination and is determined by the exclusion criteria for transplant from donors
- RECIPIENT: All subjects must have the ability to understand and the willingness to sign a written informed consent
- RECIPIENT: Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT
- RECIPIENT: Age 18 to 75 years
- RECIPIENT: Planned HCT for the treatment of the following hematologic malignancies: lymphoma (Hodgkin and non-Hodgkin), myelodysplastic syndrome, acute lymphoblastic leukemia in first or second remission, acute myeloid leukemia in first or second remission, chronic myelogenous leukemia (in first chronic or accelerated phase, or in second chronic phase), chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis (City of Hope [COH] only). Patients with multiple myeloma are excluded
- RECIPIENT: CMV seropositive
- RECIPIENT: Planned related HCT with 8/8 (A, B, C, DRB1) high resolution HLA donor allele matching
- RECIPIENT: Conditioning and immunosuppressive regimens according to institutional guidelines are permitted
- RECIPIENT: Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
- RECIPIENT: Seronegative for HIV, HCV and active HBV (surface antigen negative) within 2 months of registration
- RECIPIENT: Agreement by females of childbearing potential and males with partners of childbearing potential to use effective contraception (hormonal or barrier method or abstinence) prior to study entry and for up to 90 days post-HCT. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
Exclusion Criteria:
- TRANSPLANT FROM DONOR: Unfit to undergo standard stem cell mobilization and apheresis e.g. abnormal blood counts, history of stroke, uncontrolled hypertension
- TRANSPLANT FROM DONOR: Sickling hemoglobinopathy including HbSS, HbAS, HbSC
- TRANSPLANT FROM DONOR: Positive for human immunodeficiency virus (HIV), active hepatitis B (hepatitis B virus [HBV]), hepatitis C (hepatitis C virus [HCV]) or human T-cell lymphotropic virus (HTLV-I/II). This holds true even if donors have been already vaccinated according to criteria for donor vaccination
- TRANSPLANT FROM DONOR: Donors with impaired cardiac function are excluded. Electrocardiography is routine for potential HCT donors over 60 years old and those with a history of heart disease. Subjects in whom cardiac function is abnormal (excluding 1st degree branch block, sinus brachycardia, sinus tachycardia or non-specific T wave changes) are ineligible for Triplex vaccination
- TRANSPLANT FROM DONOR: Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the donation procedure unlikely, and making informed consent impossible
- RECIPIENT: Any prior investigational CMV vaccine
- RECIPIENT: Experimental anti-CMV chemotherapy in the last 6 months
- RECIPIENT: Planned medications from the time of HCT to day 70 post-HCT
- RECIPIENT: Live attenuated vaccines
- RECIPIENT: Medically indicated subunit (Engerix-B for HBV; Gardasil for human papillomavirus [HPV]) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections)
- RECIPIENT: Allergy treatment with antigens injections
- RECIPIENT: Alemtuzumab or any equivalent in vivo T-cell depleting agent
- RECIPIENT: Antiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)/valganciclovir (VAL), FOS, Cidofovir, CMX-001, maribavir. Acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent Herpes simplex virus (HSV)
- RECIPIENT: Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment (Letermovir is permitted). EXCEPT for low risk patients [8/8 high resolution HLA donor allele matching HCT])
- RECIPIENT: Other investigational product - concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited
- RECIPIENT: Other medications that might interfere with the evaluation of the investigational product
- RECIPIENT: Diagnosis with autoimmune disease
- RECIPIENT: Pregnant women and women who are lactating. The risks of CMV-MVA-Triplex to pregnant women are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother. Breastfeeding should be discontinued if the mother is enrolled on this study
- RECIPIENT: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., social/ psychological issues, etc
- RECIPIENT: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Donor (multi-peptide CMV-modified vaccinia Ankara vaccine)
Donors receive multi-peptide CMV-modified vaccinia Ankara vaccine injection between days -60 and -10 prior to granulocyte colony stimulating factor mobilization.
|
Given via injection
Other Names:
|
Experimental: Receipient (multi-peptide CMV-modified vaccinia Ankara vaccine)
Participants undergo hematopoietic cell transplantation on day 0 and receive multi-peptide CMV-modified Vaccinia Ankara vaccine injection on days 28 and 56.
|
Given via injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Delayed Engraftment
Time Frame: Up to 1 year from stem cell infusion.
|
Time to neutrophil engraftment was defined as days from stem cell infusion to the first of three consecutive days of absolute neutrophil count ≥0.5 x 109/L.
Delayed engraftment was defined as ≥20 days to neutrophil recovery.
|
Up to 1 year from stem cell infusion.
|
Severe (Grade III-IV) Acute Graft Versus Host Disease
Time Frame: Up to 6 months from stem cell infusion
|
Acute graft versus host disease (aGvHD) happens within days or as late as 6 months after allogeneic transplants.
The three main tissues that acute GVHD affects are the skin, liver, and gastrointestinal tract.
|
Up to 6 months from stem cell infusion
|
Number of Recipients With Grade 3-4 Adverse Events
Time Frame: Up to 1 year from stem cell infusion.
|
Toxicities were assessed in recipients by Common Terminology Criteria for Adverse Events version 4.0.
|
Up to 1 year from stem cell infusion.
|
Number of Donors With Grade 2-3 Adverse Events
Time Frame: Up to 6 months after G-CSF mobilization
|
Toxicities were assessed in recipients by Common Terminology Criteria for Adverse Events version 4.0.
|
Up to 6 months after G-CSF mobilization
|
100-Day Non-Relapse Mortality (NRM)
Time Frame: From stem cell infusion up to 100 days post-HSCT (hematopoietic stem cell transplantation).
|
NRM was defined as death without recurrent or progressive disease after allogeneic transplant.
Probabilities of NRM were estimated with the use of cumulative incidence curves, with relapse viewed as a competing risk.
|
From stem cell infusion up to 100 days post-HSCT (hematopoietic stem cell transplantation).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CMV protection
Time Frame: Up to 1 year
|
Will assess incidence of viremia (>= 1250 IU/mL), CMV viral load and use of antivirals (recipients who reactivate CMV and are given antiviral therapy will be considered intervention failures).
|
Up to 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ryotaro Nakamura, MD, City of Hope Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Virus Diseases
- Infections
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Systemic Inflammatory Response Syndrome
- Inflammation
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Sepsis
- Leukemia, Lymphoid
- Leukemia, B-Cell
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Chronic Disease
- Neoplasms
- Lymphoma
- Myelodysplastic Syndromes
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphocytic, Chronic, B-Cell
- Viremia
- Leukemia, Myeloid, Accelerated Phase
- Myeloproliferative Disorders
- Myelodysplastic-Myeloproliferative Diseases
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- 18007 (Other Identifier: City of Hope Medical Center)
- NCI-2018-01115 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic and Lymphoid Cell Neoplasm
-
University of California, San FranciscoLazarex Cancer FoundationTerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant NeoplasmUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
Clinical Trials on Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingHematopoietic Cell Transplant Recipient | Cytomegaloviral InfectionUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Diavax BiosciencesActive, not recruitingHodgkin Lymphoma | Myelofibrosis | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Lymphadenopathy | Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia in Remission | Accelerated Phase... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCytomegalovirus Infection | Healthy, no Evidence of DiseaseUnited States
-
City of Hope Medical CenterWithdrawnHodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Hematopoietic Cell Transplantation Recipient | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia in Remission | Accelerated... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingDiffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia | Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous Leukemia... and other conditionsUnited States
-
Muhimbili University of Health and Allied SciencesKarolinska Institutet; Walter Reed Army Institute of Research (WRAIR); Swedish...Completed
-
Ivan LitvinovTerminatedBasal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin CancerCanada
-
Centers for Disease Control and PreventionBavarian Nordic; Kinshasa School of Public Health; Ministry of Public Health,...Active, not recruitingMonkeypox Virus InfectionCongo, The Democratic Republic of the
-
Muhimbili University of Health and Allied SciencesKarolinska Institutet; Imperial College London; Medical Research Council; Ludwig-Maximilians... and other collaboratorsCompletedHIV | Safety | Immunogenicity | VaccinesTanzania, Mozambique